{"id":"iniparib-sar240550-bsi-201","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL1170047","moleculeType":"Small molecule","molecularWeight":"292.03"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PARP inhibitors block the repair of DNA damage, particularly single-strand breaks. In cancer cells, especially those with BRCA mutations or homologous recombination deficiency, this leads to accumulation of unrepaired DNA damage and cell death. Iniparib was developed as a PARP inhibitor to enhance the efficacy of chemotherapy agents like gemcitabine and carboplatin.","oneSentence":"Iniparib inhibits poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair, thereby sensitizing cancer cells to chemotherapy and radiation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:13.459Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic triple-negative breast cancer (in combination with chemotherapy)"},{"name":"BRCA-mutant cancers"}]},"trialDetails":[{"nctId":"NCT01593228","phase":"PHASE3","title":"Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Solid Tumors","enrollment":37},{"nctId":"NCT01204125","phase":"PHASE2","title":"Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-09","conditions":"Breast Cancer Female","enrollment":141},{"nctId":"NCT01082549","phase":"PHASE3","title":"Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-03","conditions":"Squamous Cell Lung Cancer","enrollment":780},{"nctId":"NCT01455532","phase":"PHASE1","title":"A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-11","conditions":"Neoplasm Malignant","enrollment":59},{"nctId":"NCT01045304","phase":"PHASE2","title":"Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Breast Cancer, Metastatic","enrollment":163},{"nctId":"NCT00677079","phase":"PHASE2","title":"Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer","enrollment":12},{"nctId":"NCT01086254","phase":"PHASE2","title":"SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-05","conditions":"Non-small Cell Lung Cancer Stage IV","enrollment":119},{"nctId":"NCT01161836","phase":"PHASE1","title":"An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-07","conditions":"Advanced Solid Tumors","enrollment":7},{"nctId":"NCT00938652","phase":"PHASE3","title":"A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Breast Cancer","enrollment":519},{"nctId":"NCT01213381","phase":"PHASE1","title":"Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-09","conditions":"Advance Solid Tumors","enrollment":18},{"nctId":"NCT00540358","phase":"PHASE2","title":"A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Breast Cancer","enrollment":123},{"nctId":"NCT00298675","phase":"PHASE1","title":"Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-03","conditions":"Tumors","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Iniparib (SAR240550/BSI-201)","genericName":"Iniparib (SAR240550/BSI-201)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iniparib inhibits poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair, thereby sensitizing cancer cells to chemotherapy and radiation. Used for Metastatic triple-negative breast cancer (in combination with chemotherapy), BRCA-mutant cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}